ONCAlert | Upfront Therapy for mRCC
Videos  >  

Brentuximab Vedotin Adds Benefit to A+AVD Therapy in cHL

Andrew M. Evens, DO, MSc, FACP
Published Online:3:00 PM, Tue December 3, 2019


Andrew M. Evens, DO, MSc, director of the Lymphoma Program and associate director for Clinical Services at the Rutgers Cancer Institute of New Jersey, discusses the significance of the results from the phase III ECHELON-1 trial in which patients with stage III/IV classical Hodgkin lymphoma (cHL) were treated with the combination of brentuximab vedotin (Adcetris) plus doxorubicin, vinblastine, and dacarbazine (A+AVD).

The primary endpoint was progression-free survival (PFS). The trial results demonstrated an absolute improvement of 5% in PFS by independent review panel and 6.6% by investigator. The addition may be small, Evens notes, but it means that 20 patients need to be treated with the addition of brentuximab vedotin to prevent a modified PFS in 1 patient.

A+AVD therapy is already associated with high PFS rates but adding 5% benefit to this is positive for patients with cHL. A subset analysis also demonstrated that patients with select risk factors and individual factors, such as male gender, stage IV disease, or multiple extra nodal sites, were associated with more benefit. Patients in North America, specifically, had a 12% absolute improvement, Evens concludes. Overall, a number of patients could benefit with the addition of brentuximab vedotin with their A-AVD therapy.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.